Akiyama M, et al. - In order to find out the utility and safety of tocilizumab (an anti-interleukin-6 receptor antibody) in individuals with polymyalgia rheumatica (PMR), a systematic literature review was conducted from the inception dates until August 7, 2019, including 59 a total of individuals with isolated PMR treated with tocilizumab. It was noted that tocilizumab monotherapy produced low disease activity scores in only 17% of individuals in week 4 and in only 71% of individuals even at week 12. The reduction in the cumulative glucocorticoid dose was between 58% and 70% applying a combination of tocilizumab and glucocorticoids, and 33–100% of the individuals eventually revealed glucocorticoid-free remission compared with glucocorticoid monotherapy. Tocilizumab was found to be effective in cases of isolated PMR, especially in combination with glucocorticoids. In addition to its glucocorticoid-sparing outcome, it achieves glucocorticoid-free remission and decreases relapse rates. Tocilizumab monotherapy is not recommended. No new safety effect was recorded.